Comparison of a condensed schedule of high dose cytarabine consolidation to the conventional schedule of high dose cytarabine consolidation in the treatment of acute myeloid leukemia
Phase 3
- Conditions
- Health Condition 1: C920- Acute myeloblastic leukemia
- Registration Number
- CTRI/2020/05/025475
- Lead Sponsor
- Medical College Hospital Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. De novo AML,
2. Secondary AML (sAML) with a preceding history MDS/MPN, and
3. Therapy-related AML (tAML)
Exclusion Criteria
1. Acute promyelocytic leukemia
2. Concomitant renal (creatinine > 1.5 x upper normal serum level) or hepatic (bilirubin, AST or ALP > 2 x upper normal serum level) dysfunction
3. Cardiac dysfunction (NYHA III/IV),
4. Uncontrolled infectious disease,
5. Primary coagulation disturbance,
6. Performance status (Eastern Cooperative Oncology Group) > 2
7. Active concomitant malignant disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method